Tag: SK Biopharmaceuticals
Axsome Therapeutics to acquire Sunosi from Jazz Pharmaceuticals
Axsome Therapeutics has agreed to acquire Sunosi (solriamfetol), an approved dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI), from Jazz Pharmaceuticals. Sunosi is indicated to improve ... Read More
SK Biopharmaceuticals launches phase 3 trial of seizures drug cenobamate in Asia
SK Biopharmaceuticals, a South Korean pharma company, has revealed plans to initiate a phase 3 clinical trial for its FDA-approved seizures drug cenobamate in Asia. ... Read More